Skip to main content

Early application of CVVH In the complex treatment of patients with early severe acute pancreatitis


A large population-based study of 1,024 deaths from acute pancreatitis (AP) has revealed that the median time lapse between the onset of AP and death was 6 days [1]. A number of authors considered the patients with persistent or progressive early multiple organ failure (MOF) as patients with early severe acute pancreatitis (ESAP) [2].


The aim of current study was to evaluate the efficiency of early CVVH in a complex treatment of ESAP. The retrospective analysis involved 106 patients. The patients were divided into three groups: the first group (n = 45) received CVVH dose <30 ml/kg/hour, the second group (n = 20) received the dose >30 ml/kg/hour, and in the third group (n = 41) CVVH was not used during the early phase of disease (Table 1). In the first and second groups the median time interval between admission and start of CVVH was 2 (2; 3) days.

Table 1


As compared to reference group 3, significant (P = 0.022) reduction of early mortality (14 days) was observed in the second group, and decreasing tendency (P = 0.093) of mortality rate was detected in the first group. The median time interval between admission and death was 14 days (in the first and second groups) and 5 days in the third group.


The early application of the CVVH increases time interval for care delivery and allows reducing early mortality. The best results were obtained in the group of patients who were treated with the higher dose of CVVH (earlier restoration of homeostasis and decreased severity of early MOF).


  1. 1.

    Mole DJ, et al.: HPB. 2009, 11: 166-170. 10.1111/j.1477-2574.2009.00038.x

    PubMed Central  Article  PubMed  Google Scholar 

  2. 2.

    Isenmann R, et al.: Pancreas. 2001, 22: 274-278. 10.1097/00006676-200104000-00008

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to I Aleksandrova.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Aleksandrova, I., Ilynsky, M., Rei, S. et al. Early application of CVVH In the complex treatment of patients with early severe acute pancreatitis. Crit Care 16, P362 (2012).

Download citation

  • Published:

  • DOI:


  • Pancreatitis
  • Median Time
  • Acute Pancreatitis
  • Care Delivery
  • Acute Pancreatitis